Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 7.05%
As of Monday, November 09, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 7.05%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Michael Rose
| Share Statistics | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,322.3 | $436.9 | 50% |
|
| Shares Out (Mil) | 225.5 | 46.5 | 78% |
|
| Institutional Ownership | 98.5% | 82.2% | 79% |
|
| Float (Mil) | 185.1 | 47.7 | 72% |
|
| Beta | 1.22 | 0.68 | 71% |
|
| Avg Daily Volume (000s) | 3,220 | 339 | 86% |
|
| Price Change (52-week) |
(46.8%) | 52.1% | 22% |
|
| Growth | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.5% | 6.6% | 86% |
|
| Net Income (5yr) | (11.3%) | (1.6%) | 28% |
|
| EPS (5yr) | 11.1% | 15.1% | 49 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.4%) | (15.1%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 5 | 6 | |
| Current EPS | ($0.416) | ($1.530) | ($1.594) | |
| Month Ago EPS | ($0.378) | ($1.444) | ($1.480) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.376) | ($1.430) | ($1.454) | |
| Year/Year Chg | (1.0%) | 7.7% | (15.9%) | |
| Financials | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $50 | $289 | 20% |
|
| Net Income (TTM) (Mil) | ($327) | ($11) | 4% |
|
| EPS (TTM) | ($1.457) | ($0.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($253) | ($7) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $186 | $1 | 83% |
|
| Long-Term Debt (Q1) (Mil) | $77 | $6 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,057 | $331 | 42% |
|
| Valuation | OCUL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.99 | 2.15 | 69% |
|
| P/E | na | 24.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (400.8%) | 69.5% | 0% |
|
| Net Margin | (648.6%) | 3.6% | 1% |
|
| ROA | (64.3%) | (23.3%) | 9% |
|
| ROE | (93.5%) | (24.7%) | 10% |
|
| Liabilities to Assets | 27.2% | 31.8% | 19% |
|
| F-Score | 2 | 3 | 7% |
|
Ocular Therapeutix, Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors